Table 1 The characteristics of included studies
Studies | Cases | Type of hepatocellular carcinoma | Stage of hepatocellular carcinoma(Edmonson tumor grades) | Age | Intervention | ||||
|---|---|---|---|---|---|---|---|---|---|
Apatinib +TACE group | TACE group | Apatinib +TACE group | TACE group | Apatinib +TACE group | TACE group | Durations of intervention(months) | |||
Bai 2018 [36] | 25 | 25 | SHCC | II~III | 58.34±5.67 | 59.22±5.17 | Apatinib 500 mg/d +TACE group | TACE | 3 |
Jin 2017 [37] | 20 | 22 | SHCC | II~IV | 55.24±1 0.64 | 54.12±1 1.48 | Apatinib 500 mg/d +TACE group | TACE | 3 |
Li 2018 [38] | 54 | 52 | SHCC | II~III | 53.93±5.12 | 55.20±5.25 | Apatinib 500 mg/d +TACE group | TACE | 6 |
Lu 2019 [39] | 22 | 21 | SHCC | II~III | 58.93±9.38 | 56.41±10.79 | Apatinib 500 mg/d +TACE group | TACE | 3 |
Wang 2017 [40] | 43 | 43 | SHCC | II~III | 58.28±5.21 | 58.29±5.22 | Apatinib 500 mg/d +TACE group | TACE | 3 |
Wu 2019 [41] | 28 | 31 | SHCC | II~III | 55.93±11.04 | 56.9±10.19 | Apatinib 500 mg/d +TACE group | TACE | 3 |
Zeng 2018 [42] | 38 | 38 | SHCC | NA | 56.26±4.18 | 56.48±3.85 | Apatinib 850 mg/d +TACE group | TACE | 3 |
Huang 2018 [43] | 30 | 30 | SHCC | I~III | 52.45±9.12 | 52.22±9.47 | Apatinib 850 mg/d +TACE group | TACE | 6 |
Xie 2019 [44] | 42 | 50 | SHCC | NA | 53.56±9.16 | 52.98±9.24 | Apatinib 250 mg/d +TACE group | TACE | 3 |
Cui 2019 [45] | 25 | 25 | SHCC | II~IIV | 51.62±9.64 | 52.24±9.88 | Apatinib 500 mg/d +TACE group | TACE | 3 |
Huang 2017 [46] | 38 | 38 | SHCC | II~III | 53.09±10.42 | 52.91±9.26 | Apatinib 850 mg/d +TACE group | TACE | 3 |
Wu 2018 [47] | 28 | 28 | SHCC | II~III | 52.11±10.25 | 52.42±10.71 | Apatinib 500 mg/d +TACE group | TACE | 3 |
He 2018 [48] | 50 | 50 | SHCC | II~III | 52.14±9.17 | 55.37±10.33 | Apatinib 400 mg/d +TACE group | TACE | 3 |
Li 2017 [49] | 20 | 20 | SHCC | II~IV | 49.17±10.27 | 51.06±10.12 | Apatinib 850 mg/d +TACE group | TACE | 3 |